Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%
MT Newswires Live
Oct 08
Dimerix (ASX:DXB) said the results of an analysis by Parasol are consistent with the analysis conducted last year that supported the use of proteinuria as a clinical trial endpoint for focal segmental glomerulosclerosis, a kidney disease, according to a Wednesday filing with the Australian bourse.
The company said the results cannot be disclosed as they are subject to commercial-in-confidence restrictions.
The company, along with its US partner Amicus Therapeutics, intends to seek feedback from the US Food and Drug Administration on the new findings in the coming months, the filing said.
Shares of the company rose 7% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.